Hyeon-Seok Eom Selected Research

R-CHOP protocol

1/2020	Correction to: Clinical outcomes in patients with diffuse large B cell lymphoma with a partial response to first-line R-CHOP chemotherapy: prognostic value of secondary International Prognostic Index scores and Deauville scores.
11/2017	Clinical outcomes in patients with diffuse large B cell lymphoma with a partial response to first-line R-CHOP chemotherapy: prognostic value of secondary International Prognostic Index scores and Deauville scores.
1/2010	DNA repair gene XRCC1 polymorphisms and haplotypes in diffuse large B-cell lymphoma in a Korean population.
12/2008	ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone chemotherapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hyeon-Seok Eom Research Topics

Disease

23	Multiple Myeloma 01/2022 - 07/2009
14	Neoplasms (Cancer) 01/2022 - 09/2006
12	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 10/2022 - 12/2008
7	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2022 - 07/2008
7	Lymphoma (Lymphomas) 02/2021 - 09/2010
4	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2017 - 12/2005
3	Infections 10/2022 - 12/2016
2	Febrile Neutropenia 10/2022 - 01/2022
2	Disease Progression 01/2022 - 08/2021
2	Hodgkin Disease (Hodgkin's Disease) 01/2022 - 02/2020
2	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 01/2022 - 01/2013
2	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 12/2019 - 12/2013
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2017 - 09/2014
2	Extranodal NK-T-Cell Lymphoma 12/2016 - 11/2014
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2015 - 08/2015
2	Fever (Fevers) 12/2013 - 04/2010
2	Thrombocytopenia (Thrombopenia) 12/2013 - 07/2009
1	Second Primary Neoplasms (Neoplasms, Second) 01/2022
1	Atrial Fibrillation 01/2022
1	Frailty 01/2021
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2021
1	Sepsis (Septicemia) 01/2019
1	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 09/2017
1	Chromosome Aberrations (Chromosome Abnormalities) 09/2017
1	Aplastic Anemia (Anemia, Hypoplastic) 09/2017
1	Chromothripsis 09/2017
1	Hemolysis 09/2017
1	Hyperbilirubinemia 12/2016
1	B-Cell Lymphoma (Lymphoma, B Cell) 12/2016
1	Philadelphia Chromosome 11/2015

Drug/Important Bio-Agent (IBA)

11	Rituximab (Mabthera)FDA Link 10/2022 - 12/2008
11	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2022 - 12/2008
10	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2022 - 12/2008
10	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 07/2009
9	Vincristine (Oncovin)FDA LinkGeneric 10/2022 - 12/2008
9	Bortezomib (Velcade)FDA Link 01/2021 - 07/2009
7	Prednisone (Sone)FDA LinkGeneric 11/2017 - 12/2008
6	Thalidomide (Thalomid)FDA Link 01/2022 - 05/2010
6	Lenalidomide (CC 5013)FDA Link 08/2021 - 01/2014
5	Melphalan (Alkeran)FDA LinkGeneric 11/2020 - 05/2010
4	R-CHOP protocolIBA 01/2020 - 12/2008
3	Prednisolone (Predate)FDA LinkGeneric 10/2022 - 05/2010
3	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2022 - 01/2016
3	Pharmaceutical PreparationsIBA 01/2022 - 09/2017
3	Busulfan (Busulfex)FDA Link 11/2020 - 01/2018
2	Brentuximab VedotinIBA 01/2022 - 04/2020
2	defibrotideIBA 01/2022 - 01/2013
2	AlbuminsIBA 01/2021 - 09/2017
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2017 - 03/2012
2	Interleukin-10 (Interleukin 10)IBA 01/2017 - 12/2016
2	Asparaginase (Elspar)FDA Link 12/2016 - 11/2014
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 11/2016 - 09/2016
2	AntigensIBA 01/2014 - 09/2006
2	CytokinesIBA 07/2008 - 01/2008
1	pegfilgrastim (Neulasta)FDA Link 10/2022
1	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022
1	Dacarbazine (DIC)FDA LinkGeneric 01/2022
1	Immunoconjugates (Immunoconjugate)IBA 01/2022
1	Bleomycin (Blenoxane)FDA LinkGeneric 01/2022
1	zanubrutinibIBA 01/2022
1	Vinblastine (Vinblastine Sulfate)FDA Link 01/2022
1	carfilzomibIBA 08/2021
1	C-Reactive ProteinIBA 01/2021
1	ibrutinibIBA 01/2021
1	AntibodiesIBA 06/2020
1	Cytarabine (Cytosar-U)FDA LinkGeneric 02/2020
1	Etoposide (VP 16)FDA LinkGeneric 02/2020
1	Methylprednisolone FDA LinkGeneric 02/2020
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 02/2020
1	pomalidomideIBA 01/2020
1	Immunologic Factors (Immunomodulators)IBA 01/2020
1	Proteasome InhibitorsIBA 01/2020
1	10-propargyl-10-deazaaminopterin FDA Link 12/2019
1	daratumumabIBA 01/2019
1	Histone Deacetylase InhibitorsIBA 10/2018
1	CKD-581IBA 10/2018
1	eculizumab FDA Link 09/2017
1	SteroidsIBA 01/2017
1	Alkylating AgentsIBA 01/2017
1	dimemorfan (AT 17)IBA 01/2017
1	CreatinineIBA 12/2016
1	Methotrexate (Mexate)FDA LinkGeneric 12/2016
1	plerixafor FDA Link 03/2016
1	Imatinib Mesylate (Gleevec)FDA Link 11/2015
1	nilotinib FDA Link 08/2015

Therapy/Procedure

13	Therapeutics 01/2022 - 12/2008
9	Stem Cell Transplantation 01/2022 - 07/2009
9	Drug Therapy (Chemotherapy) 01/2020 - 12/2008
5	Combination Drug Therapy (Combination Chemotherapy) 02/2020 - 04/2012
4	Transplantation 01/2022 - 12/2006
3	Hematopoietic Stem Cell Transplantation 01/2017 - 01/2013
2	Cell Transplantation 01/2022 - 08/2015
2	Immunotherapy 06/2020 - 09/2010
2	Aftercare (After-Treatment) 01/2020 - 09/2017
2	Induction Chemotherapy 01/2019 - 09/2017
2	Chemoradiotherapy 12/2016 - 11/2014
1	Blood Component Removal (Apheresis) 02/2021
1	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 01/2019
1	Consolidation Chemotherapy 12/2016
1	Hematopoietic Stem Cell Mobilization 01/2016